MedPath
Found 363 clinical trials|View Analysis
Sort by:

Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis

Phase 2
Recruiting
Conditions
Biphenotypic Acute Leukemia
Acute Lymphoblastic Leukemia
Myeloblastic Leukemia
Bilinear Leukemia
Malignant Lymphoma, Non-Hodgkin
Myelodysplastic Syndrome
First Posted Date
2025-01-01
Last Posted Date
2025-01-01
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
50
Registration Number
NCT06756152
Locations
🇷🇺

National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov, Moscow, Russian Federation

Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone As Initial Treatment in Patients Diagnosed with Chronic Graft-versus-host Disease At a Grade of Moderate or Higher Severity

Phase 2
Not yet recruiting
Conditions
GVHD - Graft-Versus-Host Disease
Haematopoietic Stem Cell Transplantation
Neoplasms
Interventions
First Posted Date
2025-01-01
Last Posted Date
2025-01-01
Lead Sponsor
Byung-Sik Cho
Target Recruit Count
88
Registration Number
NCT06756061
Locations
🇰🇷

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Banpo-daero/Seocho-gu, Korea, Republic of

Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

Phase 2
Not yet recruiting
Conditions
Aplastic Anemia
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Transplantation
Procedure: Computed Tomography
Drug: Cyclosporine
Drug: Fludarabine
Drug: Granulocyte Colony-Stimulating Factor
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Ruxolitinib
Drug: Sirolimus
Radiation: Total-Body Irradiation
First Posted Date
2024-12-31
Last Posted Date
2024-12-31
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
20
Registration Number
NCT06752694
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus

Phase 2
Recruiting
Conditions
Vitiligo
Interventions
Drug: Ruxolitinib Cream 1.5%
Drug: Aqueous cream
First Posted Date
2024-12-05
Last Posted Date
2024-12-05
Lead Sponsor
Hospital Authority, Hong Kong
Target Recruit Count
20
Registration Number
NCT06719024
Locations
🇭🇰

Queen Mary Hospital, Hospital Authority, Hong Kong, Hong Kong

Upfront Ruxolitinib for Chronic Graft-vs-host Disease

Phase 1
Recruiting
Conditions
Chronic Graft Versus Host Disease
Interventions
First Posted Date
2024-11-19
Last Posted Date
2024-11-19
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
30
Registration Number
NCT06695507
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.

Phase 1
Completed
Conditions
Atopic Dermatitis
Interventions
First Posted Date
2024-11-05
Last Posted Date
2024-11-05
Lead Sponsor
Taro Pharmaceuticals USA
Target Recruit Count
476
Registration Number
NCT06673654
Locations
🇺🇸

Taro Pharmaceuticals USA Inc., Hawthorne, New York, United States

A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor

First Posted Date
2024-10-30
Last Posted Date
2024-10-30
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
39
Registration Number
NCT06664970
Locations
🇨🇳

Bing Han, Beijing, China

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Phase 2
Recruiting
Conditions
Chronic Graft-versus-host Disease (cGVHD)
Interventions
First Posted Date
2024-10-28
Last Posted Date
2024-12-27
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
120
Registration Number
NCT06660355
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

Recruiting
Conditions
Pregnancy Related
Atopic Dermatitis
Interventions
First Posted Date
2024-10-04
Last Posted Date
2024-12-10
Lead Sponsor
Incyte Corporation
Target Recruit Count
5621
Registration Number
NCT06627335
Locations
🇺🇸

Syneos Health (remote site), Morrisville, North Carolina, United States

A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis

Phase 2
Not yet recruiting
Conditions
Myelofibrosis
Interventions
Drug: Ruxolitinib
Drug: INCB57643
First Posted Date
2024-09-30
Last Posted Date
2024-09-30
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT06619522
Locations
🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath